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Abstract The aggregation of K-synuclein in dopaminergic neu-
rons is a critical factor in the etiology of Parkinson’s disease
(PD). Oxidative and nitrative stress is also implicated in PD.
We examined the e¡ect of nitration on the propensity of
K-synuclein to ¢brillate in vitro. Fibril formation of K-synuclein
was completely inhibited by nitration, due to the formation of
stable soluble oligomers (apparently octamers). More impor-
tantly the presence of sub-stoichiometric concentrations of ni-
trated K-synuclein led to inhibition of ¢brillation of non-modi-
¢ed K-synuclein. These observations suggest that nitration of
soluble K-synuclein may be a protective factor in PD, rather
than a causative one.
( 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Parkinson’s disease (PD) is an age-related neurodegenera-
tive disorder that a¡ects approximately one million people in
the USA. PD symptoms are attributed to the progressive loss
of dopaminergic neurons from the substantia nigra region of
the brain. Some surviving nigral dopaminergic neurons con-
tain cytosolic ¢lamentous inclusions known as Lewy bodies
(LBs) and Lewy neurites [1,2]. Substantial evidence indicates
the involvement of K-synuclein in the pathogenesis of PD. For
example, ¢brillar K-synuclein is a major component of LBs
[3], and the A53T and A30P mutations in K-synuclein have
been identi¢ed in familial early-onset PD [4,5]. The produc-
tion of K-synuclein in transgenic mice [6] or in transgenic £ies
[7] leads to motor de¢cits and neuronal inclusions reminiscent
of PD.
K-Synuclein is a small (14 kDa), abundant, presynaptic pro-
tein [8,9]. K-Synuclein has four tyrosines, Tyr39, Tyr125,
Tyr132 and Tyr135. Structurally, puri¢ed K-synuclein belongs
to the rapidly growing family of intrinsically unstructured
(natively unfolded) proteins [10^19], which have little or no
ordered structure under physiological conditions, due to a
unique combination of low overall hydrophobicity and large
net charge [20]. In vitro, K-synuclein forms ¢brils with mor-
phologies and staining characteristics similar to those ex-
tracted from disease-a¡ected brain [21^26].
Oxidative injury has been implicated in the pathogenesis of
PD [27,28]. Nitration of tyrosine residues in proteins arises
from the action of oxygen and nitric oxide and their products,
especially peroxynitrite. The existence of extensive and wide-
spread accumulation of nitrated K-synuclein (i.e. protein con-
taining the product of tyrosine nitration, 3-nitrotyrosine) in
the LBs from patients with PD, dementia with LB, the LB
variant of Alzheimer’s disease, and multiple system atrophy
has been demonstrated using antibodies to speci¢c nitrated
tyrosine residues in K-synuclein [27,28]. It has been concluded
that the selective and speci¢c nitration of K-synuclein in these
disorders may directly link oxidative and nitrative damage to
the onset and progression of neurodegenerative synucleinopa-
thies [27]. In addition, the exposure of K-synuclein to peroxy-
nitrite in vitro or in cell cultures leads to both nitration of all
four tyrosines of K-synuclein and dityrosine cross-linking, as
well as oligomerization of K-synuclein [29,30].
Little is known about the detailed e¡ects of tyrosine nitra-
tion on the ¢brillation of K-synuclein, although recent inves-
tigations suggest that it is the formation of intermolecular
dityrosine cross-links that is responsible for the enhanced
K-synuclein association [29,31]. Here, we describe the e¡ect
of nitration on the ¢brillation properties of human recombi-
nant K-synuclein in vitro, and its e¡ect on the ¢brillation of
normal K-synuclein. Surprisingly, nitration of K-synuclein
leads to inhibition of ¢brillation.
2. Materials and methods
2.1. Expression and puri¢cation of human K-synuclein
Human wild type K-synuclein was expressed using Escherichia coli
BL21 (DE3) cell line transfected with pRK172/K-synuclein wild type
plasmid (generously provided by M. Goedert, MRC, Cambridge,
UK). The protein was puri¢ed according to the published procedure
[21,32].
2.2. Supplies and chemicals
Thio£avin T (ThT) was obtained from Sigma (St. Louis, MO,
USA), tetranitromethane (TNM) from Aldrich. All other chemicals
were of analytic grade from Fisher. All bu¡ers and solutions were
prepared with nanopure water and stored in plastic vials.
2.3. UV absorbance spectroscopy
UV absorbance spectra were determined with semimicro quartz
cuvettes (Hellma) with a 5 mm light path using a UV-2401 spectro-
photometer (Shimadzu, Japan). Protein quanti¢cation was determined
using absorption maxima of 275 for control and 428 nm for nitrated
K-synuclein. The concentration of nitrated protein was calculated ac-
cording to [33].
2.4. Oxidation of K-synuclein by TNM
Nitrated K-synuclein was prepared by adding a 50 Wl aliquot of 1%
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TNM in ethanol to 500 Wl of 4^5 mg/ml protein solution. The reaction
mixture was stirred vigorously at room temperature for 10 min and
then another 50 Wl aliquot of 1% TNM solution was added [34]. After
10 min of stirring the mixture was dialyzed with four changes of
appropriate bu¡er at pH 7.8 to completely remove unreacted TNM.
Success of oxidation was con¢rmed by mass spectrometry (MS) anal-
ysis (MicroMass Quattro II). Samples for MS analysis were prepared
by diluting 2 Wl of protein solution in 200 Wl of 50% acetonitrile/50%
pH 2.0 HCl.
2.5. Fibril formation assay
Fibril formation of oxidized and non-oxidized K-synuclein was
monitored in a £uorescence plate reader (Fluoroskan Ascent). Protein
solutions contained 20 WM ThT and 1.0 mg/ml (70 WM) K-synuclein in
40 mM phosphate/100 mM NaCl bu¡er at pH 7.5. We have previ-
ously shown that the presence of ThT does not a¡ect the kinetics of
¢brillation. Samples were run in quadruplicate or quintuplicate at
37‡C with shaking as described previously [11].
2.6. Fluorescence measurements
Fluorescence measurements were determined using a FluoroMax-3
spectro£uorometer (Instruments S.A., Jobin Yvon Horiba, France)
with a 1 ml quartz cuvette (Hellma) and 1 cm excitation pathlength.
2.7. Estimation of hydrodynamic dimensions
Stokes radii were determined using a DynaPro Molecular Sizing
Instrument (Protein Solutions, Lakewood, NJ, USA) at K-synuclein
concentration of 0.1 mg/ml using a 1.5 mm pathlength 12 Wl quartz
cuvette. Prior to measurement, solutions were ¢ltered with a 0.1 Wm
Whatman Anodisc-13 ¢lter. Size-exclusion chromatography high per-
formance liquid chromatography (SEC HPLC) analysis was per-
formed with a TSK-GEL G2000SWXL size-exclusion column using
a Waters 2695 system (Waters, Milford, MA, USA) and a Wyatt
Mini-DAWN dynamic light scattering and RI detector.
2.8. Lowry assay
Aliquots of 50 Wl sample were centrifuged at 13 000 rpm for 20 min.
Supernatant was removed and mixed with 50 Wl of bu¡er while the
pellet was resuspended in 100 Wl of bu¡er for each sample tested.
Supernatant and resuspended pellet were added separately to a mix-
ture of 2 ml reagent A and 0.2 ml 50% Folin reagent [35]. After
vigorous mixing, samples were allowed to sit for 2 h to complete
the reaction.
2.9. Electron microscopy
Negatively stained electron microscope images were taken using
Formvar/carbon grids (Ted Pella, Redding, CA, USA). Grids were
prepared by incubation of two-fold diluted protein samples for 10
min, followed by washing three times with water, negative staining
with uranyl acetate for 5 min, and then washing with water.
3. Results
3.1. In vitro nitration of human K-synuclein
Electrospray ionization MS analysis of K-synuclein prior to
the oxidative modi¢cation gave a molecular mass of 14 460S 3
Da, which is in agreement with the calculated value based on
the amino acid sequence (14 460 Da). The conditions used for
the in vitro modi¢cation of K-synuclein result in nitration of
all four tyrosines, as evidenced by the MS peak positioned
at 14 642S 3 Da, which corresponds to the mass of human
K-synuclein with four nitrated tyrosine groups (14 640 Da).
3.2. Nitration of K-synuclein inhibits ¢brillation
ThT is a £uorescent dye that interacts with amyloid ¢brils
leading to an increase in £uorescence intensity in the vicinity
of 480 nm [36]. Fig. 1 compares ¢brillation patterns of non-
modi¢ed and nitrated K-synuclein monitored by ThT £uores-
cence. Fibril formation for the non-oxidized K-synuclein at
neutral pH is characterized by a typical sigmoidal curve, re-
£ecting nucleated polymerization. In contrast, there was no
evidence of ¢bril formation by nitrated K-synuclein at neutral
pH on the time-scale shown. In fact, ¢brils were not formed
even after incubation of modi¢ed K-synuclein for 300 h.
After incubation at pH 7.5, 37‡C for 300 h with stirring, the
solutions of non-modi¢ed and modi¢ed K-synuclein were sub-
jected to centrifugation and subsequent analysis of superna-
tants and pellets by the Lowry protein assay. Results of this
analysis are shown in Fig. 2A as relative amount of soluble
and insoluble protein in each sample. Fig. 2A shows that most
of the non-modi¢ed protein was insoluble, whereas the vast
majority of the nitrated K-synuclein was in the supernatant,
i.e. soluble. This observation shows that nitrated K-synuclein
forms neither ¢brils, nor amorphous aggregates.
In agreement with earlier studies [11,17,37], incubation of
non-modi¢ed K-synuclein solution at low pH leads to signi¢-
cant acceleration of the ¢brillation process (Fig. 1). This may
be attributed to the pH-induced stabilization of a partially
folded intermediate, which represents a crucial primary step
in the K-synuclein ¢brillation pathway [11]. Fig. 1 shows that
both non-nitrated and nitrated forms of K-synuclein ¢brillate
at similar rates at low pH. This means that the inhibitory
e¡ect of nitration is eliminated under conditions favoring for-
mation of the critical partially folded intermediate. Fig. 2B
represents the results of Lowry assays, which con¢rm that
non-nitrated and nitrated K-synucleins both form mostly in-
soluble deposits (i.e. ¢brils) at acidic pH.
3.3. Nitrated K-synuclein forms stable oligomers
In order to obtain more information about the association
state of non-modi¢ed and nitrated K-synuclein during the in-
cubations, the hydrodynamic radii of both forms of the pro-
tein at the early stages of ¢brillation were estimated using
dynamic light scattering (DLS). These DLS experiments
were performed in parallel with the analysis of the reaction
mixtures by SEC and the ThT assay. Initially the Stokes ra-
dius, RS, of the non-modi¢ed protein was 32S 2 AT . This value
is in good agreement with the results of previous studies
[11,17,32,38], and corresponds to the monomeric natively un-
folded K-synuclein. At early incubation times (well before the
beginning of the ¢bril formation detected by the characteristic
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Fig. 1. Nitration of K-synuclein inhibits ¢brillation. Kinetics of ¢-
brillation of non-modi¢ed (circles) and nitrated K-synuclein (trian-
gles) monitored by ThT £uorescence intensity. Measurements were
performed at 37‡C and pH 7.5 (open symbols) or pH 3.0 (black
symbols) in 20 mM bu¡er containing 100 mM NaCl with 70 WM
K-synuclein.
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increase in the ThT £uorescence intensity) DLS showed that
the majority of the non-modi¢ed protein was monomeric and
characterized by a slightly increased RS value (V35^37 AT )
due to the presence of a small amount of dimer. This value
of the Stokes radius represents a weighted average between
monomer and dimer, due to technical limitations of the in-
strument. Corresponding SEC analyses also indicated the
presence of a small amount of dimer. Furthermore, at these
pre-¢brillation time points, DLS demonstrated that a small
fraction of non-modi¢ed protein formed large oligomers, the
size of which increased monotonically from V200 to V2000
AT (RS), in accord with previous reports using di¡erent tech-
niques [39]. Finally, almost no monomeric or small oligomeric
species were detected when ¢brils started to form, and the
majority of protein in the soluble fraction of the reaction
mixture possessed an RS of s 400 AT .
In contrast, even at time zero (i.e. at the beginning of the
incubation) DLS showed that the majority of the nitrated
K-synuclein (96%) formed small oligomers with RS of
62S 3 AT , whereas the remainder of the protein was present
as larger oligomers (RS of 160S 10 AT ). Parallel SEC/DLS
analysis revealed that octamers represented the predominant
species in the reaction mixture, but some dimers and tetramers
were also present. The size and relative population of small
oligomers did not change signi¢cantly during the incubation,
whereas the small fraction of larger oligomers showed a time-
dependent increase in RS from 160 to 350 AT . The data thus
indicate that nitrated K-synuclein has an increased propensity
to form stable oligomers compared to normal, unmodi¢ed
K-synuclein.
Fig. 2. K-Synuclein aggregation is inhibited by nitration. Incubated
samples were centrifuged and the supernatant and pellet fractions
analyzed for protein content using the Lowry assay. K-Synuclein (70
WM) was incubated in 20 mM bu¡er containing 100 mM NaCl at
37‡C for 300 h. Panel A at pH 7.5, and panel B at pH 3.0. Panel C
represents the results of inhibition studies on non-modi¢ed K-synu-
clein ¢brillation in the presence of di¡erent concentrations of ni-
trated K-synuclein. The numbers show the molar ratios of the ni-
trated to non-modi¢ed protein. Black and gray bars represent the
relative protein contents in the supernatant and pellet, respectively.
Fig. 3. Nitrated K-synuclein inhibits ¢brillation of non-modi¢ed
K-synuclein. A: Raw data. B: Normalized £uorescence intensity.
The ¢brillation kinetics were monitored by ThT £uorescence for 70
WM non-nitrated K-synuclein in 20 mM Na-phosphate bu¡er, 100
mM NaCl, pH 7.5 in the absence (black circles) or presence of 2.0
(inverted triangles), 1.0 (open squares), 0.50 (open diamonds), 0.25
(open triangles) and 0.10 (open hexagons) molar equivalents of the
nitrated protein.
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3.4. Nitrated K-synuclein inhibits ¢brillation of the
non-modi¢ed protein
Fig. 3A shows that the addition of nitrated K-synuclein to a
solution of non-modi¢ed K-synuclein leads to very e¡ective
inhibition of ¢brillation of the non-modi¢ed protein, and a
signi¢cant decrease in the amount of ThT £uorescence was
observed when the ratio of modi¢ed protein to non-modi¢ed
K-synuclein was as low as 1:10. Fig. 3B shows that both lag-
time and elongation rate are substantially a¡ected by the ad-
dition of nitrated K-synuclein at sub-stoichiometric levels. The
extent of these e¡ects depends on the relative concentration of
the modi¢ed protein, with larger concentrations showing
stronger inhibitory e¡ects. In fact, ¢brillation was not ob-
served (at least within the time-scale studied) when the ratio
of nitrated to non-modi¢ed K-synuclein was 2:1 and higher.
Analysis of the data presented in Fig. 3B revealed that the
duration of the lag-time was 22.5 S 0.5, 33.3S 0.6, 41.3 S 0.6,
63.6S 0.7 and 106.7 S 0.8 h, whereas the elongation rate
was 0.113S 0.002, 0.0456S 0.0009, 0.0278S 0.0006, 0.0179S
0.0004 and 0.0082S 0.0002 h31 when the ratio of nitrated to
non-modi¢ed K-synuclein was 0, 1:1, 1:2, 1:4 and 1:10, re-
spectively.
SEC analysis of incubation mixtures of nitrated and un-
modi¢ed K-synuclein showed nitrotyrosine absorbance in the
peak corresponding to the octamer (data not shown), indicat-
ing that these oligomers were hetero-oligomers. Fig. 2C shows
that the amount of insoluble material decreases with increase
in the relative concentration of the nitrated protein. Thus,
nitrated K-synuclein e¡ectively inhibited both ¢brillation and
amorphous aggregate formation from the non-modi¢ed pro-
tein.
3.5. Morphology of K-synuclein ¢brils
Electron micrographs con¢rmed the lack of ¢brils after in-
cubation of either nitrated K-synuclein (Fig. 4B) or a 1:1
mixture with unmodi¢ed protein (Fig. 4C). The few ¢brils
observed from the nitrated K-synuclein were essentially indis-
tinguishable from those of non-modi¢ed K-synuclein, Fig. 4A.
Magni¢cation of the image in Fig. 4C shows the presence of
many spherical-shaped oligomeric intermediates of about 50^
60 nm diameter (Fig. 4D).
4. Discussion
The data presented in this study unambiguously show that
nitration of K-synuclein, in the absence of covalent dityrosine
cross-linking, inhibits ¢brillation in vitro. The mechanism of
this inhibition involves formation of stable soluble oligomers,
which are located o¡ the ¢brillation pathway. Perhaps more
importantly, nitrated K-synuclein inhibits ¢brillation of non-
modi¢ed K-synuclein, even at sub-stoichiometric concentra-
tions. In fact, e¡ective inhibition of the ¢brillation of non-
modi¢ed protein occurred even when the nitrated K-synuclein
accounted for only 10% of total protein. Notably, all three
kinetic parameters characterizing the ¢brillation assay, lag-
time, elongation rate, and ¢nal intensity, showed strong de-
pendence on the relative concentration of the nitrated protein.
These results suggest that interaction between nitrated and
non-modi¢ed forms of human K-synuclein leads to the forma-
tion of very stable hetero-oligomers, as seen in Fig. 4D. The
formation of these non-¢brillogenic oligomers e¡ectively de-
creases the concentration of ¢brillation-prone non-modi¢ed
Fig. 4. Negatively stained transmission electron micrographs of
K-synuclein ¢brils prepared for the non-modi¢ed (A) and nitrated
protein (B), as well as for the 1:1 mixture of modi¢ed and non-
modi¢ed proteins (C). The scale bar indicates 2 Wm in panels A^C.
Panel D is a magni¢ed image of panel C, showing spherical-shaped
oligomeric intermediates (scale bar is 500 nm).
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protein, and thus inhibits both the formation of nuclei and the
growth of nascent ¢brils. Fibrillation of recombinant K-synu-
clein has been shown to be strongly dependent on protein
concentration [40]. The SEC data indicated that the molecular
mass of the predominant oligomers of nitrated K-synuclein
corresponded to an octamer. The fact that as little as 10%
of nitrated K-synuclein inhibited ¢brillation is consistent
with the formation of hetero-oligomers consisting of approx-
imately one nitrated to 10 unmodi¢ed K-synucleins.
We have previously shown that methionine-oxidized K-syn-
uclein also suppressed ¢brillation of K-synuclein. However,
the mechanism of that inhibition was di¡erent, as oxidized
protein a¡ected primarily the duration of the lag-time, and
did not a¡ect the rate of elongation [37]. Similar inhibitory
e¡ects have been described for several pairs of homologous
proteins. Examples include human L-/K- and Q-/K-synucleins
[17] ; mouse/wild type human and mouse/A53T human K-syn-
ucleins [41] ; AL40/AL42 [42] ; non-¢brillogenic Q-chain/¢brillo-
genic mutant L-chain of hemoglobin [43].
The stable oligomeric intermediates formed by, and in the
presence of, nitrated K-synuclein, are similar to the species
termed proto¢brils by Lansbury and coworkers [39,44,45].
Since these species may form annular channels in membrane
vesicles, they have been suggested as the potentially neuro-
toxic species in PD [44].
It is widely accepted that aggregation of K-synuclein is in-
volved in the etiology of PD. It is also believed that oxidative
stress may represent one of the key determinants in develop-
ment of the disease [27^30,46]. In particular, it has been
shown that extensive and widespread accumulation of nitrated
K-synuclein is found in the Lewy bodies of PD and related
synucleinopathies.
Based on these observations it has been concluded that the
selective and speci¢c nitration of K-synuclein in these disor-
ders provides evidence to directly link oxidative and nitrative
damage to the onset and progression of neurodegenerative
synucleinopathies [27]. However, our in vitro data on the ef-
fect of nitration of human K-synuclein on its ¢brillation con-
tradict these conclusions. In fact, we have shown that nitra-
tion e¡ectively inhibits ¢brillation of K-synuclein. Moreover,
the addition of sub-stoichiometric concentrations of nitrated
K-synuclein inhibits the ¢brillation of non-modi¢ed K-synu-
clein due to the formation of non-productive hetero-oligo-
mers. Our observations are consistent with the hypothesis
that it is the formation of covalent intermolecular dityrosine
cross-links, rather than nitration, which is responsible for
K-synuclein ¢brillation under oxidative conditions.
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